Division of Thermo Fisher Scientific Inc.
Latest From Affymetrix Inc.
Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio
GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.
The last month of 2016 saw a final flurry of medtech M&A activity as companies rushed to seal deals before the New Year arrived. Medtech Insight's M&A data tracker recorded twice as many deals in December compared to the previous month, but that was not enough to boost the year's tally, which fell behind 2015.
Chrono Therapeutics Inc. has hired two ex-Shire PLC executives to lead clinical development for the recently acquired pipeline programs it picked up from the Irish pharma company. Meanwhile, Apellis Pharmaceuticals Inc., Ascendis Pharma A/S, Intrexon Corporation and Proteostasis Therapeutics Inc. have made senior appointments and Araim Pharmaceuticals has named a new chair for its board of directors.
Enzo and Illumina settle patent battle; Bard and Gore argue over jury logistics for an upcoming trial; and former employee alleges False Claims Act violations by medical equipment maker Lincare.
Drug Discovery Tools
- Nanotechnology, Chips, etc.
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Thermo Fisher Scientific Inc.
- Senior Management
Frank Witney, PhD, Pres. & CEO
Gavin Wood, EVP, CFO
David Weber, PhD, EVP, Chief Commercial Officer
- Contact Info
Phone: (408) 731-5000
3420 Central Expwy.
Santa Clara, CA 95051
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.